Meriofert

Luteinising hormone (human), Follicle‑stimulating hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable preparation for intramuscular or subcutaneous use. It is used to treat infertility related to anovulation, hypogonadotropic hypogonadism, and to support assisted reproductive technologies such as in‑vitro fertilisation. The product contains a combination of human LH and FSH that mimics natural pituitary secretion.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert, a gonadotropin preparation, is indicated for conditions involving impaired ovarian function and hormonal deficiency. - Infertility due to anovulation: stimulates follicular development and induces ovulation. - Hypogonadotropic hypogonadism: replaces deficient LH and FSH to restore normal gonadal function. - Assisted reproductive technology (e.g., in vitro fertilisation): supports controlled ovarian stimulation for oocyte retrieval.

Meriofert may be associated with a range of adverse reactions following injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Headache: transient headache of varying intensity. - Nausea: occasional nausea without vomiting. - Abdominal discomfort: mild abdominal cramps or bloating. - Ovarian hyperstimulation syndrome (mild): mild symptoms such as abdominal distension.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): marked ovarian enlargement, ascites, thromboembolism. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reaction: rash, urticaria, or anaphylaxis. - Ectopic pregnancy: occurrence of pregnancy outside the uterus. - Multiple pregnancy: higher‑order gestations (triplets or more).

Before using Meriofert, clinicians should consider several precautionary measures to minimise risks. - Patient assessment: evaluate ovarian reserve and baseline hormone levels. - Monitoring: perform regular ultrasound and estradiol monitoring during treatment. - OHSS risk: assess risk factors such as polycystic ovary syndrome and adjust dose accordingly. - Contraindications: avoid use in known hypersensitivity to gonadotropins or active ingredients. - Pregnancy status: discontinue if pregnancy is confirmed before intended ovulation trigger. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert can interact with other medications that affect hormonal balance or coagulation.

Major Interactions (Avoid): - GnRH agonists/antagonists: may alter the intended gonadotropin response. - Anticoagulants: increased risk of bleeding with severe ovarian hyperstimulation. - Aromatase inhibitors: may interfere with estrogen synthesis during stimulation.

Moderate Interactions (Monitor Closely): - Corticosteroids: may affect ovarian response, requiring dose adjustment. - Thyroid hormones: abnormal thyroid status can modify gonadotropin efficacy. - Insulin or oral hypoglycemics: hyperstimulation may affect glucose metabolism.